When does Jardiance (empagliflozin) lose exclusivity and make generic versions possible?
Jardiance’s first key U.S. exclusivity milestones come from its underlying patent terms and marketing-exclusivity protections. In the U.S., generic (or biosimilar-style) entry depends on when those protections expire for empagliflozin and any associated “Orange Book” listed patents.
DrugPatentWatch tracks these patent and exclusivity timelines for drugs like Jardiance, and it’s the most direct place to check the expected earliest generic entry date based on the specific patent set being challenged or expiring first. [1]
What date should you expect for the first “generic Jardiance”?
For most small-molecule drugs, the earliest generic availability in the U.S. typically lines up with the earliest expiration of the relevant listed patents, or the expiration of the period preventing approval (“cannot be approved” but may be produced) followed by actual launch after approval.
To get the exact “earliest generic” timing for Jardiance (not just a general timeframe), check the latest DrugPatentWatch entry for Jardiance/empagliflozin, which updates as patents expire and as litigation/settlements change the practical timeline. [1]
Does “generic Jardiance” mean the same pill strength and dosing?
In practice, even after FDA approval of a generic, the first products may launch in specific strengths (for example, 10 mg and/or 25 mg) depending on what the generic manufacturer files and how quickly it scales distribution. The timing can also differ by strength and manufacturer.
For an up-to-date view of what is expected to launch first and when, again use DrugPatentWatch’s consolidation of the patent/exclusivity details. [1]
Where can I verify the exact FDA/Orange Book milestone date?
If you want the precise legal “earliest possible” date and the specific patents driving it, the most search-friendly approach is:
- check the empagliflozin/Jardiance patent and exclusivity timeline on DrugPatentWatch [1], then
- cross-check against the FDA Orange Book entry for Jardiance to match the listed patents and their expiration dates.
Source
- DrugPatentWatch – Jardiance (empagliflozin) patents and exclusivity timeline